Refine by
Tumor Specificity Suppliers & Manufacturers
43 companies found
based inGaithersburg, MARYLAND (USA)
NexImmune is a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIMâ„¢) technology. AIM nanoparticles act as synthetic dendritic cells to deliver ...
NexImmune’s AIM™ platform is the foundation for our unique approach to immunotherapy. Our AIM nanoparticle technology enables the development of immunotherapies that orchestrate specific T cell function and trigger a ...
based inEttlingen, GERMANY
We are a pioneering medical device company focused on transforming the lives of patients with difficult to treat cancers by applying our discoveries in bioelectromagnetics to targeted treatment of cancer. Our patient-based research using low and ...
The TheraBionic P1 produces low levels radiofrequency (RF) electromagnetic fields, which are amplitude-modulated at tumor-specific frequencies. The device is coupled with a spoon-shaped antenna, which is placed in ...
based inBoston, MASSACHUSETTS (USA)
SOPHiA GENETICS is the creator of a global data-sharing network – we work with customers from over 790 institutions in over 70 countries. Our network advances data-driven medicine to improve health outcomes and economics worldwide. We offer a ...
Rise above the noise to see what truly matters. Elevate your precision oncology program. Push the boundaries of your in-house liquid biopsy capabilities with MSK-ACCESS® powered with SOPHiA DDM™, a decentralized version of the rigorously ...
based inOslo, NORWAY
NEC OncoImmunity AS is an artificial intelligence (AI) driven biotech company offering proprietary machine-learning based software, which addresses the key knowledge gaps in the prediction of bona fide immunogenic antigens for personalized cancer ...
The NEC Immune Profiler Provides an Holistic Approach to Antigen Presentation Prediction. NEC OncoImmunity AS has developed an AI engine for its clinical projects, known as the NEC Immune Profiler, that predicts from next generation sequencing data ...
based inPhiladelphia, PENNSYLVANIA (USA)
Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity ...
Our goal is to revolutionize cancer therapy on a global basis by developing TCR T-cell therapies (called SPEAR T-cells) with the potential to treat a wide range of cancer types and patients. Our TCR T-cell therapies have advantages over other immune ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating NRP-1, and transforms the solid tumor microenvironment into a ...
based inAbingdon, UNITED KINGDOM
PsiOxus is a clinical-stage company redefining therapies for solid tumors with the goal of curing patients with cancer. Our clinically validated, systemically dosed T-SIGn® viral vector platform delivers tumor-localized production of combinations of ...
based inFrankfurt, GERMANY
NeraCare develops and commercializes molecular diagnostic tests for patients with skin cancer. The tests provide actionable, tumor-specific information for each individual patient. The information is used to make improved treatment decisions, i.e. ...
based inHouston, TEXAS (USA)
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) is a public biopharmaceutical company based in the Houston, TX area that is developing GP2, a novel peptide immunotherapy, and has commenced a Phase III clinical trial, called Flamingo-01. GP2 is derived ...
Following breast cancer surgery, a HER2/neu 3+ patient receives trastuzumab (Genentech/Roche’s Herceptin, a monoclonal antibody treatment that targets the HER2/neu protein) in the first year and then hopes that their breast cancer will not ...
based inMontpellier, FRANCE
SurgiMAb develops injectable fluorescent conjugates to be used during Fluorescence-Guided Surgery (FGS) by oncology surgeons so they can clearly delineate tumors and visualize infra-clinical size nodules invisible to their naked eyes. SurgiMab was ...
SurgiMab’s tumor-targeting fluorescent molecules enable real time visualization of tumor margins, tumor spread and micro-tumors which are invisible to the naked eye. As ...
based inWoodinville, WASHINGTON (USA)
Cancer Targeted Technology is designing and patenting small molecular weight enzyme inhibitors with unique and exceptional imaging and drug delivery properties. Cancer Targeted Technology (CTT) develops innovative targeted agents for cancer that ...
CTT’s lead therapeutic product, CTT1403, is a PSMA-targeted 177Lu-labeled agent for prostate cancer that can has superior binding characteristics, long circulation half-life, enhanced tumor uptake and unparalleled ...
based inSchlieren, SWITZERLAND
We want to empower people to deal with their malignant cells through their own immune system just like we deal with viral infections. Today’s cancer immunotherapies are powerful but, to the detriment of their effect, not very tumor-selective. ...
CDR-Life’s T cell engaging antibodies are potentially transformative in the field of cancer immunotherapies» Prof. Markus G. Manz, MD, Head of Medical Oncology and Hematology at University Hospital and University of Zurich, Switzerland. ...
based inUtrecht, NETHERLANDS
At LAVA, we are focused on applying our expertise in gamma-delta T cell engagers. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor ...
based inMorrisville, NORTH CAROLINA (USA)
Our mission is to provide comprehensive personalized molecular solutions to inform cancer care. NantOmics, a member of the NantWorks ecosystem of companies, is a leader in molecular diagnostic testing and the first company to employ an integrated ...
based inBerlin, GERMANY
JPT Peptide Technologies GmbH is a leading provider of custom peptides and innovative peptide-based services and products. We are a research and development partner for projects in immunotherapy and vaccine Development, immune monitoring, proteomics ...
PepSup is a highly standardized, peptide-based cell activation (cell stimulation) assay designed to produce short-term culture supernatants for analysis of cytokines or other mediators of interest. We create your PepSup Cell Activation Kit with your ...
based inBreitenfurt, AUSTRIA
Privately held OncoQR ML, based in Vienna/Austria, is a pre-clinical biotech company that offers novel therapeutic cancer vaccines based on its unique, proprietary and broadly applicable S-TIR™ (Specific Total Immune Remodulation) technology ...
Cancer cells have the ability to escape our immune system´s defenses – by outsmarting checkpoint molecules on our immune cells. For more than three decades, science and industry have been working to overcome cancer’s tricky battle ...
based inSan Diego, CALIFORNIA (USA)
Invivoscribe is a global leader in molecular diagnostics, providing a comprehensive range of standardized, CE-marked in vitro diagnostic products and companion diagnostics for hematology-oncology. The company's offerings include research use only ...
based inCambridge, MASSACHUSETTS (USA)
Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with ...
based inSeattle, WASHINGTON (USA)
Aptevo Therapeutics is a biotech company focused on bringing novel immuno-oncology therapeutics to market. We leverage the innovative ADAPTIR™ and ADAPTIR-FLEX platform technologies to create therapeutic candidates designed to improve outcomes for ...
APVO603 is a dual agonist bispecific antibody employing a novel mechanism of action to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family. Dual targeting of 4-1BB and OX40 provides synergistic ...
based in, CHINA
Mol Scientific provides customized peptide synthesis services including linear peptides, modified peptides, protein cross-linked peptides and more. Mol Scientific is a national high-tech enterprise, committed to providing high quality products and ...
Mol Scientific offer high-quality Tumor-specific antigenic peptide 1 product(MPE0003074). Mol Scientific committed to bring our esteemed customers high quality products and the finest services at highly competitive ...